Journal info
|
||
Select Journal
Journals
Acta Virologica Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2023 2022 Ahead of print 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.69, No.4, p.976–982, 2022 |
||
| Title: Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer | ||
| Author: Jin-Fei Si, Jing Xiang, Jing-Wen Wei, Yue Hao, Zheng-Bo Song | ||
| Abstract: We aimed to explore the treatment efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung squamous cell carcinoma (SCC) patients and identify potential beneficial subgroups of EGFR-mutated lung SCC patients in this study. Between February 1st, 2013 and December 1st, 2021, 657 advanced lung SCC patients were enrolled at Zhejiang Cancer Hospital. Amplification refractory mutation system PCR or next-generation sequencing were used to detect gene abnormality. Clinicopathological features were analyzed by chi-square test and the clinical results of lung SCC patients who received first-generation EGFR-TKI were analyzed by the Kaplan-Meier method. Lung SCC patients harboring EGFR mutation accounted for 11.0% in this study. Of 657 lung SCC patients, the median PFS and OS of 116 patients who received targeted therapy were 3.6 months and 16.2 months, patients treated with targeted therapy had similar OS to patients without targeted therapy (p = 0.839). Of 110 lung SCC patients who received first-generation EGFR-TKI, EGFR-mutated patients had long PFS (p = 0.000) but similar OS (p = 0.472) than patients with EGFR wide type. EGFR-mutated SCC patients who received first-generation EGFR-TKI as a first-line benefit are equal to patients who received first-generation EGFR-TKI as the second line or beyond according to similar PFS (p = 0.311) and OS (p = 0.721) between them. In addition, there was also no significant difference in PFS (p = 0.376) and OS (p = 0.205) between patients with exon 19 deletion and L858R point mutation. Lung SCC patients harboring EGFR mutation received first-generation EGFR-TKI had better clinical survival than patients with EGFR wide type. |
||
| Keywords: epidermal growth factor receptor (EGFR); exon 19 deletion (19 del); L858R mutation; lung squamous cell cancer (lung SCC) | ||
| Published online: 23-May-2022 | ||
| Year: 2022, Volume: 69, Issue: 4 | Page From: 976, Page To: 982 | |
| doi:10.4149/neo_2022_220329N348 |
||
|
Price:
16.80 €
|
||
|
|
||